Open in interactive viewer → charts, metric popovers & call review

Eisai's Subcutaneous Bet Is Working Before the Formulary Even Opens

IQLIK is pulling patients 4x faster than IV and prescribers 6x faster — and the Japan pen launch and January 2027 Part D inclusion are still ahead, not behind.
ESALY · Earnings Call · 2026-11-10

The Hurdle Came Down, and the Curve Bent

For three years the bear case on LEQEMBI was not efficacy — it was friction. Beds, chairs, infusion slots, two-hour drives, and a Medicare exception process that made a neurologist's office look like a paperwork factory. Eisai's fiscal Q2 (reported 10 November) is the first quarter where that friction visibly stopped being the binding constraint. Guidance headline first, because it was good and unremarkable: revenue JPY 470bn, up 17.5%, with the pharmaceutical business at JPY 462.1bn; operating profit JPY 41.4bn (+20.4%) and core operating profit JPY 43.1bn (+28.6%). “Revenue for the second quarter reached JPY 470 billion, a 17.5% increase compared to the same period of the previous year.” — Takuya Oyama, CFO · 2026-11-10 The three "3L" franchises added JPY 59.1bn of revenue between them — LENVIMA +28.2bn, DAYVIGO +10.4bn, LEQEMBI +20.4bn — and everything else added another JPY 10.8bn on top. The unremarkable part ends there. What is new is the shape of the LEQEMBI launch curve after the August 24 U.S. launch of IQLIK for initiation treatment with IQLIK. CEO Haruo Naito put numbers on it that no prior call had: patient uptake running roughly four times the IV trajectory, prescriber counts compounding at roughly six times. “In comparison to that, at 6x faster pace, uptake is increasing in the number of prescribers. A very rapid uptake is being realized.” — Haruo Naito, CEO · 2026-11-10 The U.S. prescriber base is broadening beyond the AAT-converted — into rural physicians for whom a drive was disqualifying and urban GPs for whom parking was. And critically, the new-patient share of anti-amyloid therapy has flipped to a leading position, above half, per Katsuya Haruna.

In the past, there was only IV infusion option for LEQEMBI, but that hurdle has been lowered significantly with this added option.

Haruo Naito, CEO · 2026-11-10
That is the whole thesis in one sentence. The auto-injector did not create new pharmacology; it removed a logistical veto. Sixty-one point five billion yen of H1 LEQEMBI revenue, up 50%, against a full-year forecast of JPY 143.5bn, is now looking conservative rather than brave.

What the Skeptics Said, and What Changed

This is where the prior calls earn their keep. In May 2025, Naito described the U.S. as being in a demand-stimulation phase, not a demand-expansion phase: “the U.S. is now approaching the end of demand stimulation phase.” — Haruo Naito, CEO · 2025-05-15 The phrase implied PCP activation, blood-based confirmatory testing, and subcutaneous administration were all prerequisites sitting in the future. The other recurring fear was messier: that shifting reimbursement from Medicare Part B to Part D would stall a launch, because another company had visibly struggled with exactly that handoff. In August 2025, Morgan Stanley's Muraoka pressed it directly: “pen was launched by another company, but they were struggling in the switching from B to D.” — Shinichiro Muraoka, Analyst · 2025-08-05 And in November 2025, Macquarie's Tony Ren framed January 2027 as a long wait: “if we have to wait until January 2027, that does appear to be quite far away.” — Tony Ren, Analyst · 2025-11-05 Both of those concerns just got partially retired, and in the same quarter. Part D formulary inclusion from January 2027 now covers roughly two-thirds of commercial lives with no step therapy and no distinction between the 250mg and 350mg presentations: “As regards to Medicare Part D, about 67% will be secured, and there has been progress towards that.” — Katsuya Haruna, Head of Global LEQEMBI Business · 2026-11-10 Haruna confirmed the figures are comparable with Biogen's disclosure because the two companies share the data. The out-of-pocket math is the underrated detail: the cap sits at $2,100, and 55% of patients on IQLIK have already reached it, meaning zero marginal out-of-pocket for the majority of the current base. And the demand expansion arrived early. The inflection is happening with Part D still six weeks from launch and with the Japanese 250mg pen — JPY 27,141 per pen, plus roughly JPY 600 in home-injection guidance fees — only listing on 13 November. Two catalysts that were supposed to be the reason to wait are now upside to a curve that is already bending. The thematic read-across is not confined to Eisai. The reimbursement process for patients is the same knot being untied across healthcare this quarter, and the broader market has been paying for the site of service migration — care moving out of infusion chairs and into homes and ambulatory settings — as a top-tier advancer over the trailing year. Eisai is, unusually, at the front of that wave rather than riding it. The diagnostic side is moving too: blood-based biomarker names including Eisai itself have been among the better-performing healthcare clusters over the last 90 days, which matters because the confirmatory-testing bottleneck is the remaining gate on PCP-led initiation.

The Guidance They Did Not Raise, and the Market They Lost

Here is the tension. Revenue progress at 53.2% and operating profit at 59.2% of plan through six months, with a JPY 70bn full-year operating profit target, is an invitation to upgrade. Eisai declined it — with a straight face but a well-worn script. “As of today, quantitative uncertainty factors are not recognized by us yet. However, on the other hand, as far as we can recognize in China, impact of VBP, volume-based pricing, can bring about some impact.” — Takuya Oyama, CFO · 2026-11-10 That sentence does a lot of work, because it quietly absorbs the quarter's bad news. LEQEMBI did not get onto China's NRDL; Naito was emphatic that the government made that call, not Eisai, and the drug instead landed on a commercial insurance list, with volume-based pricing a live risk. This is the item that has been the subject of analyst questions for at least three consecutive calls — Sakai asked about NRDL timing in November 2025 — and it has now resolved, negatively, into something management would rather bury inside a guidance paragraph than headline. Equally notable is what has dropped out of the conversation. Cost of sales discipline — the ratio sits at 22.3%, up about half a point sequentially on product mix and LEQEMBI production-loss timing — drew a pointed question in the current call, much as it did in May and November 2025. The difference is that the earlier answers were about structural reductions; today's is about containment within plan. A company no longer talking about de-risking its own P&L is a company that believes the P&L is de-risked. The fundamental value of maintenance treatment also got unusually explicit treatment this quarter — 48-month durability data, the ARIA and infusion-reaction profile, the argument that Alzheimer's is progressive and therefore stopping treatment is the error. That is a subtle shift in message: from winning the first prescription to defending the lifetime value of the patient. For a drug that has to be given indefinitely to have value, that framing is the whole monetisation story.

Where the Next Leg Comes From

Management spent the back half of the call on three shots that are not in the guidance: preclinical Alzheimer's (the DIAD / DIAN-TU ART cohort run with Washington University, lecanemab for five years in asymptomatic mutation carriers), etalanetug as a potential first-in-class anti-tau agent stacked on top of LEQEMBI in the Tau NexGen Phase II/III, and ledasorexton in narcolepsy with Phase II top-line due before fiscal year-end, framed by Haruna as a future blockbuster. On partnering for tau, R&D head Ido was deliberately non-committal — "considering both" — which is the language of a company keeping its options rather than its commitments open. The macro backdrop is genuinely new, and it is not pharma-specific. Eisai's Americas head noted that Democrats have captured both chambers, which reframes the U.S. policy path toward greater Congressional oversight of drug pricing and China-related bills — a theme that now sits near the top of the market's keyword map as a new Congress reshapes the legislative queue. With MFN pricing and tariffs still unresolved and China's access route still undefined, the refusal to raise guidance looks less like conservatism and more like a company that has learned what a policy headline can do to a launch curve. So: a strong quarter, an early and real product inflection, two unspent catalysts, one lost market, and a management team that has finally stopped describing demand expansion as a future phase and started reporting it in the present tense. The market capitalisation is roughly $17.6bn. The narrative is now about whether the curve is durable or a launch artefact — and the January 2027 formulary data point, not this quarter's, is the one that will settle it.